Viewing stories from August, 2023

28 August 2023
Change of Company Secretary (ASX Announcement)

Starpharma today announces, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period.

Read More

24 August 2023
Appendix 4G – Corporate Governance Statement (ASX Announcement)

Starpharma today releases its Appendix 4G – Key to Disclosures Corporate Governance Council Principles and Recommendations, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.

Read More

14 August 2023
Starpharma to receive A$6.5M from Mundipharma and rights to VivaGel® BV (ASX Announcement)

Starpharma today announces it has negotiated a commercial settlement agreement with Mundipharma in relation to the VivaGel® BV product.

Read More

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.